Effect of Cardiovascular Comorbidities on Disease Severity and Quality of Life in Patients With Acute Exacerbation of Non-cystic Fibrosis Bronchiectasis
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- assessment of BNP (Brain natriuretic peptide) pg/ml levels in patients with bronchiectasis and cardiovascular comorbidities.
研究概览
简要总结
Effect of cardiovascular comorbidities on disease severity and quality of life in Patients with acute exacerbation of non-cystic fibrosis bronchiectasis
详细描述
The study will include patients with bronchiectasis, and in an attempt to correlate the effect and burden of cardiovascular comorbidities in those patients, we will study the quality of life in those patients in comparison to the control group ( patients with bronchiectasis and without any other comorbidities) using SF-36 quality of life questionnaire. We will also study the inflammatory markers in both groups using D-dimer, BNP, and CRP and correlate them with the frequency of hospital admission, the severity of symptoms, and the general health state.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Any Patients with Bronchiectasis had no comorbidities other than cardiovascular comorbidities during the study period.
排除标准
- •Any Patients who refuse to participate in the study.
- •Any other comorbidity or end-organ failure may affect the study's result.
研究组 & 干预措施
Patient with bronchiectasis and cardiovascular comorbidities
Patients with Bronchiectasis had no comorbidities other than cardiovascular comorbidities during the study period.
干预措施: Echocardiography (Device)
Patients with bronchiectasis and without cardiovascular comorbidities
Patients with Bronchiectasis had no comorbidities.
干预措施: Echocardiography (Device)
结局指标
主要结局
assessment of BNP (Brain natriuretic peptide) pg/ml levels in patients with bronchiectasis and cardiovascular comorbidities.
时间窗: March 2023 to September 2023
Serum BNP (Brain natriuretic peptide) pg/ml will be compared in both groups.
Assessment of Quality of life in patients and control groups using The Short Form (36) Health Survey (SF-36)
时间窗: March 2023 to September 2023
The Short Form (36) Health Survey will be performed in both groups. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
次要结局
- Hospitalization frequency in patient group compared to control group.(March 2023 to September 2023)
研究者
Ahmad Shaddad
Lecturer of pulmonary medicine Assuit university
Assiut University